Halozyme Therapeutics (HALO) Free Cash Flow Growth (3y) (2013 - 2026)
Halozyme Therapeutics (HALO) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
814,307.08 Bn |
814,307.05 Bn |
- |
- |
| 2 |
Belite Bio |
55,320.00 Bn |
55,320.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,149.72 Bn |
17,149.72 Bn |
- |
- |
| 4 |
Legend Biotech |
3,590.00 Bn |
3,589.71 Bn |
242.10 Mn |
24.91% |
| 5 |
Akari Therapeutics |
1,650.72 Bn |
1,650.72 Bn |
- |
20.11% |
| 6 |
Evaxion A |
1,522.09 Bn |
1,522.07 Bn |
- |
- |
| 7 |
Psyence Biomedical |
229.39 Bn |
229.38 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.09 Bn |
105.85 Bn |
2.59 Bn |
14.71% |
| 9 |
Abivax |
90.15 Bn |
90.15 Bn |
- |
- |
| 10 |
Halozyme Therapeutics |
8.24 Bn |
7.92 Bn |
297.47 Mn |
32.63% |
| Date | Value |
|---|
| Mar 31, 2026 |
32.63% |
| Dec 31, 2025 |
40.81% |
| Sep 30, 2025 |
36.77% |
| Jun 30, 2025 |
35.51% |
| Mar 31, 2025 |
48.12% |
| Dec 31, 2024 |
28.66% |
| Sep 30, 2024 |
-2.07% |
| Jun 30, 2024 |
12.06% |
| Mar 31, 2024 |
30.16% |
| Dec 31, 2023 |
19.50% |
| Sep 30, 2023 |
185.27% |
| Jun 30, 2023 |
187.85% |
| Mar 31, 2023 |
158.36% |
| Dec 31, 2022 |
70.29% |
| Sep 30, 2022 |
61.80% |
| Jun 30, 2022 |
51.25% |
| Mar 31, 2022 |
130.40% |
| Dec 31, 2021 |
88.66% |
| Sep 30, 2021 |
100.48% |
| Jun 30, 2021 |
57.23% |
